Analysis of disparities in time to allogeneic transplantation in adults with acute myelogenous leukemia
Open Access
- 26 July 2023
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (15) , 3824-3833
Abstract
Although alternative donors extend transplant access, whether recipient ancestry affects the time to allogeneic transplant is not established. We analyzed the likelihood of clinically significant delays to allograft by patient ancestry in 313 adult patients with acute myelogenous leukemia (AML) who underwent transplantation. Non-European ancestry patients (n = 99) were more likely than Europeans (n = 214) to receive HLA-mismatched donor allografts (45% vs 24%). Overall, the median time from transplant indication to allograft was 127 days (range, 57-1683). In multivariable analysis, non-Europeans had an increased risk of prolonged indication to transplant time >180 days owing to significant delays in indication to consult >90 days and consult to transplant >120 days. Compared with recipients of HLA-matched unrelated donors (URDs), HLA-mismatched adult donor recipients were at an increased risk of delayed indication to transplant, whereas HLA-identical sibling and cord blood recipients were at a lower risk. Subanalysis showed more indication to transplant delays >180 days in non-European (44%) vs European (19%) 8/8 URD recipients. Finally, the pandemic further exacerbated delays for non-Europeans. In summary, although non-European patients with AML are less likely to receive 8/8 URDs as expected, if they do, their transplants are delayed. HLA-identical siblings and cord blood facilitate the fastest transplants regardless of patient ancestry, whereas other adult donor transplants are delayed. Strategies to mitigate referral barriers, hasten donor evaluation, and use all alternative donor sources are critical to ensure timely transplantation for patients with AML.Keywords
This publication has 35 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Cord-Blood Transplantation in Patients with Minimal Residual DiseaseNew England Journal of Medicine, 2016
- HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the U.S. RegistryNew England Journal of Medicine, 2014
- Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stageBone Marrow Transplantation, 2014
- How I assess comorbidities before hematopoietic cell transplantationBlood, 2013
- Practice variation in physician referral for allogeneic hematopoietic cell transplantationBone Marrow Transplantation, 2012
- Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provisionBone Marrow Transplantation, 2012
- Availability of Cord Blood Extends Allogeneic Hematopoietic Stem Cell Transplant Access to Racial and Ethnic MinoritiesTransplantation and Cellular Therapy, 2010
- Searching for unrelated donor hematopoietic stem cells: Availability and speed of umbilical cord blood versus bone marrowTransplantation and Cellular Therapy, 2002
- Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemiaThe Lancet, 2000